Skip to main content
Premium Trial:

Request an Annual Quote

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group, a maker of lateral flow tests, says, according to the Financial Times.

It adds that while employer access to free tests has wound down in England, free lateral flow kits have still been publicly available at pharmacies or from a government website. Innova has in particular supplied the UK with more than 1.5 billion lateral flow devices under contracts worth more than £4 billion, FT says.

But Dan Elliott, Innova's chief executive, tells it that he would be "surprised" if free testing past the spring and that he was preparing for a shift to a retail environment. He notes, though, that the end date of the program would likely depend on SARS-CoV-2 infection rates.

As FT adds, there have been questions about the accuracy of lateral flow tests. In June, the US Food and Drug Administration warned against using the Innova test, saying that its performance has not been adequately established, as 360Dx reported then.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.